Scarpellini A, Germack R, Lortat-Jacob H, Muramatsu T, Billett E, Johnson T, Verderio E, Journal of Biological Chemistry, 2009, 284:18411-1842 Fibronectin-tissue transglutaminase matrix rescues ...

Integrins are very attractive therapeutic targets in oncology. The anti-tumor mechanisms of integrin-targeting drugs have been validated both in vitroand in vivo. Integrin-targeting drugs are ...

Department of Nuclear Medicine, TUM University Hospital and Central Institute for Translational Cancer Research, (TranslaTUM), School of Medicine, Technical University Munich, 81675 Munich, Germany ...

THR-149 is one of a pair of drugs Oxurion has in mid-stage testing for DE along with pan-RGD integrin antagonist THR-687, which is in the phase 2 INTEGRAL study in previously-untreated DME patients.